Legacy Wealth Management (Idaho)’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Wealth Management (Idaho)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.8K	Buy	78 +6	+8%	+$2.8K	0.02%	319
2025 Q4	$32.6K	Buy	72 +6	+9%	+$2.59K	0.02%	271
2025 Q3	$25.8K	Hold	66	–	–	0.01%	243
2025 Q2	$29.4K	Sell	66 -1	-1%	-$461	0.02%	205
2025 Q1	$32.5K	Hold	67	–	–	0.02%	185
2024 Q4	$31.4K	Buy	67 +1	+2%	+$464	0.02%	158
2024 Q3	$32.6K	Buy	+66	New	+$31.7K	0.02%	151

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Legacy Wealth Management (Idaho)'s VRTX Position: Q1 2026 in Review

Legacy Wealth Management (Idaho) increased its Vertex Pharmaceuticals (VRTX) stake by 8.3% in Q1 2026, buying an estimated $2.8K and bringing the position to 78 shares worth $34.8K. The position accounts for 0.02% of the portfolio, ranked #319.

Legacy Wealth Management (Idaho) first reported a position in VRTX in Q3 2024 and has held it in 7 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Legacy Wealth Management (Idaho) held 78 shares of Vertex Pharmaceuticals worth $34.8K as of Q1 2026.
Legacy Wealth Management (Idaho) bought 6 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.8K.
Vertex Pharmaceuticals made up 0.02% of Legacy Wealth Management (Idaho)'s portfolio in Q1 2026, its #319 holding.
Legacy Wealth Management (Idaho) first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q1 2026, filed 7 May 2026.